Filtros de búsqueda

Lista de obras de Georgina V. Long

(18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma.

artículo científico publicado en 2012

1259TiPA randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600

21. Recurrent hotspot SF3B1 mutations in mucosal melanoma: Frequency and impact on survival

artículo científico publicado en 2019

23. Prevalence and expression profile of immune checkpoint receptors in untreated human melanoma

artículo científico publicado en 2019

24. Analysis of indoleamine 2,3-dioxygenase expression in longitudinal primary, nodal and distant metastatic melanoma specimens

artículo científico publicado en 2019

3-Amino-6,6′-bis(methoxycarbonyl)-2,2′-bipyridine, a model for the central chelation unit of streptonigrin

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

artículo científico publicado en 2016

3302 Safety and Activity of Combined Radiotherapy (RT) and Anti-PD-1 Antibodies (PD-1) in Patients (pts) with Metastatic Melanoma

3304 Metabolic activity in metastatic melanoma after long-term treatment with anti-PD-1 antibodies

3305 PD1 inhibition-induced changes in melanoma and its associated immune infiltrate

A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265).

artículo científico publicado en 2015

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis

artículo científico publicado en 2019

A case series of immune checkpoint inhibitor induced diabetes mellitus (ICI-DM).

artículo científico publicado en 2018

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition

artículo científico publicado en 2014

A phase II, open-label, randomized, multicenter trial of encorafenib + binimetinib evaluating a standard-dose and a high-dose regimen in patients with BRAFV600-mutant melanoma brain metastasis (MBM) (POLARIS) ⬇️

scholarly article

AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma

artículo científico publicado en 2013

Abstract 2650: In depth immune profiling of the response of melanoma to MAPK inhibition

Abstract 2822: Low intestinal microbial diversity is associated with severe immune-related adverse events and lack of response to neoadjuvant combination antiPD1, anti-CTLA4 immunotherapy

scholarly article

Abstract 3246: Dynamics of T-cell checkpoint receptor profiles during melanoma progression

scholarly article

Abstract 5025: Immune expression profiling of MAPK inhibitor resistant tumors based upon mechanisms of resistance

Abstract 81: The association between melanoma liver metastases (mets) and the systemic anti-tumor immune profile

artículo científico publicado en 2023

Abstract 975: Liver metastases (mets) induce systemic immunosuppression and immunotherapy resistance in metastatic melanoma

scholarly article

Abstract A024: Protein microarrays for the immunological profiling of melanoma

scholarly article by Jessica Duarte et al published January 2016 in Cancer immunology research

Abstract CT120: A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM)

scholarly article

Abstract S02-01: Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI)

artículo científico publicado en 2020

Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib.

artículo científico

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

artículo científico publicado en 2015

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

artículo científico publicado en 2013

Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma

artículo científico publicado en 2016

Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma

artículo científico publicado en 2014

Acute Radiation Skin Toxicity Associated With BRAF Inhibitors.

artículo científico publicado en 2014

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

artículo científico publicado en 2017

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

artículo científico publicado en 2017

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

artículo científico publicado en 2018

Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial

scientific article published on 25 September 2019

Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial

artículo científico publicado en 2020

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial ⬇️

artículo científico publicado en 2021

Advanced cancer patients' attitudes towards, and experiences with, screening for somatic mutations in tumours: a qualitative study.

artículo científico publicado en 2016

Advanced melanoma patients with high CD16+ macrophages have better response and survival to anti-PD-1 based immunotherapy ⬇️

scholarly article

Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting ⬇️

artículo científico publicado en 2019

Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology

scientific article published on 21 March 2019

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations.

artículo científico publicado en 2018

Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials ⬇️

scholarly article

Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma

scientific article published on 29 November 2019

Anatomic position determines oncogenic specificity in melanoma

artículo científico publicado en 2022

Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA

artículo científico publicado en 2022

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

artículo científico publicado en 2022

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.

artículo científico publicado en 2016

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection

article

Antibacterial agents based on the cyclic D,L-alpha-peptide architecture

artículo científico publicado en 2001

Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma.

artículo científico publicado en 2013

Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006

Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer.

artículo científico publicado en 2018

Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.

artículo científico publicado en 2018

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial

scientific article published on 02 January 2020

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials

artículo científico publicado en 2020

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.

artículo científico publicado en 2018

Atrophic exocrine pancreatic insufficiency associated with anti-PD1 therapy

artículo científico publicado en 2017

Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition

artículo científico publicado en 2012

Australian general practitioners' attitudes and knowledge of sentinel lymph node biopsy in melanoma management

artículo científico publicado en 2020

BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume

artículo científico publicado en 2015

BRAF inhibitor activity in V600R metastatic melanoma

artículo científico publicado en 2012

BRAF inhibitor activity in V600R metastatic melanoma--response.

artículo científico publicado en 2013

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

artículo científico publicado en 2014

BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting

BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.

artículo científico publicado en 2016

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma.

artículo científico publicado en 2013

Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design

artículo científico publicado en 2020

Bilateral facial neuritis associated with dabrafenib and trametinib after failure of neoadjuvant immunotherapy for stage III melanoma

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

artículo científico publicado en 2017

Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma

artículo científico publicado en 2017

CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment

artículo científico publicado en 2018

CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells

artículo científico publicado en 2020

CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function

scientific article published on 20 March 2019

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series

artículo científico publicado en 2016

Characterisation of peripheral blood mononuclear cells in patients with combination ipilimumab and nivolumab therapy-related colitis

artículo científico publicado en 2019

Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial

artículo científico publicado en 2014

Characterization of the treatment-naive immune microenvironment in melanoma with <i>BRAF</i> mutation

artículo científico publicado en 2022

Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes

artículo científico publicado en 2019

Checkpoint inhibitors for cancer immunotherapy. Multiple checkpoints on the long road towards cancer immunotherapy.

artículo científico publicado en 2015

Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy

scientific article published on 16 October 2020

Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy

article

Circulating tumor DNA (ctDNA) using Guardant360 to predict response in BRAF V600 WT metastatic melanoma (MM) patients (pts) receiving immune checkpoint inhibitors (ICI).

artículo científico publicado en 2020

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma

artículo científico publicado en 2015

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.

artículo científico publicado en 2017

Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

artículo científico publicado en 2023

Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion

artículo científico publicado en 2015

Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma.

artículo científico publicado en 2012

Clinical factors and overall survival (OS) associated with patterns of metastases (mets) in melanoma patients (pts) ⬇️

scholarly article

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing

artículo científico publicado en 2017

Clinico-pathologic correlates of BRAF mutation status in 207 consecutive patients with metastatic melanoma

Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors

artículo científico publicado en 2015

Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab

artículo científico publicado en 2020

Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients

artículo científico publicado en 2019

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.

artículo científico publicado en 2018

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor

artículo científico publicado en 2014

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

artículo científico publicado en 2012

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

artículo científico publicado en 2014

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

artículo científico publicado en 2019

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

artículo científico publicado en 2015

Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i

artículo científico publicado en 2020

Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma

scientific article published on 02 November 2019

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma

artículo científico publicado en 2012

Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) ⬇️

artículo científico publicado en 2019

Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes

artículo científico publicado en 2022

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, o

article

Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making

artículo científico publicado en 2016

Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients

artículo científico

Comprehensive Characterization of Cancer Driver Genes and Mutations

article

Comprehensive analysis of cutaneous and uveal melanoma liver metastases

artículo científico publicado en 2020

Computer-assisted diagnosis for skin cancer: have we been outsmarted?

artículo científico publicado en 2017

Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas.

artículo científico publicado en 2014

Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase II OpACIN-neo trial ⬇️

scholarly article

Copper(II) bipyridyl and iminopyridyl analogoues of streptonigrin

Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials.

artículo científico publicado en 2015

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.

artículo científico publicado en 2014

Corrigendum to “Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*” [Eur J Cancer 91 (2018) 116–124]

artículo científico publicado en 2018

Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.

artículo científico publicado en 2016

Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis

artículo científico publicado en 2021

Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma

scientific article published on 28 January 2020

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma

artículo científico

Cutaneous toxicities of RAF inhibitors.

artículo científico

Dabrafenib and its potential for the treatment of metastatic melanoma

artículo científico publicado en 2012

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

artículo científico publicado en 2015

Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma

artículo científico publicado en 2014

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

artículo científico publicado en 2012

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

artículo científico publicado en 2012

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

artículo científico publicado en 2017

Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)

artículo científico publicado en 2019

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

artículo científico publicado en 2017

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

artículo científico publicado en 2019

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

artículo científico publicado en 2019

Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA

artículo científico publicado en 2020

Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies

artículo científico publicado en 2020

Diagnosis and treatment of KIT-mutant metastatic melanoma

artículo científico publicado en 2013

Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.

artículo científico publicado en 2014

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma

artículo científico publicado en 2019

Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials

artículo científico

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

artículo científico publicado en 2019

Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma

artículo científico publicado en 2019

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

scientific article published on 24 April 2012

Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).

artículo científico publicado en 2014

Durability of response to immune checkpoint inhibitors (ICI) in metastatic Merkel cell carcinoma (mMCC) after treatment cessation.

artículo científico publicado en 2021

Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.

artículo científico publicado en 2017

Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment.

artículo científico publicado en 2014

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

scientific article published on 12 July 2016

Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression.

artículo científico publicado en 2013

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy

artículo científico publicado en 2016

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.

artículo científico publicado en 2017

Efficacy of immune checkpoint inhibitors for in-transit melanoma

scientific article published on 01 May 2020

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

artículo científico publicado en 2019

Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas

artículo científico publicado en 2014

Epigenetic profiling for the molecular classification of metastatic brain tumors

artículo científico publicado en 2018

Estimation of Distant Metastasis-free Survival in Trials of Adjuvant Therapy for Melanoma. Reply

scientific article published on 01 April 2019

Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors.

artículo científico publicado en 2014

Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients

artículo científico publicado en 2017

Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care.

artículo científico publicado en 2011

Expanded access programmes: patient interests versus clinical trial integrity

artículo científico publicado en 2014

Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma

artículo científico publicado en 2015

External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma

scientific article published on 16 July 2019

FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma

artículo científico publicado en 2018

Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma

artículo científico publicado en 2013

Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy.

artículo científico publicado en 2015

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials

artículo científico publicado en 2016

Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis.

artículo científico publicado en 2018

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

article

Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma.

artículo científico publicado en 2014

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

scientific article published on 02 September 2020

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

artículo científico publicado en 2020

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

artículo científico publicado en 2019

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

artículo científico publicado en 2019

From dismal prognosis to rising star: melanoma leading the way with new generation cancer therapies.

artículo científico publicado en 2015

Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility

artículo científico publicado en 2020

Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy

artículo científico publicado en 2018

Germline variants are associated with increased primary melanoma tumor thickness at diagnosis

artículo científico publicado en 2021

Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma

artículo científico publicado en 2015

Health-related quality of life results from the phase III CheckMate 067 study.

artículo científico publicado en 2017

Heterogeneity of FDG-PET response to GSK2118436, an inhibitor of oncogenic mutant BRAF-kinase in BRAF-mutant metastatic melanoma

High response rate to PD-1 blockade in desmoplastic melanomas

artículo científico publicado en 2018

Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting

artículo científico publicado en 2022

Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report

artículo científico publicado en 2020

Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma

artículo científico publicado en 2020

Histopathology of pembrolizumab-induced hepatitis: a case report.

artículo científico publicado en 2017

Hotspot KRAS mutations in brain metastases at the first metastatic recurrence of cutaneous melanoma

artículo científico publicado en 2020

Hypermethylation of Circulating Free DNA in Cutaneous Melanoma ⬇️

scholarly article

IMMU-04. TEMPORAL AND SPATIAL MODULATION OF THE IMMUNE RESPONSE OF THE MURINE GL261 GLIOMA TUMOUR MICROENVIRONMENT ⬇️

artículo científico publicado en 2019

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

artículo científico publicado en 2019

Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol paper for a mixed methods study

artículo científico publicado en 2020

Immune mediated neuropathy following checkpoint immunotherapy

artículo científico publicado en 2017

Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.

artículo científico publicado en 2013

Impact of genomics on the surgical management of melanoma.

artículo científico publicado en 2018

Improved overall survival in melanoma with combined dabrafenib and trametinib

artículo científico publicado en 2015

Incidence of new primary melanomas after diagnosis of stage III and IV melanoma.

artículo científico publicado en 2013

Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies

scientific article published on 03 March 2019

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.

artículo científico publicado en 2014

Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma

artículo científico publicado en 2014

Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients

scientific article published on 31 October 2018

Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors

artículo científico publicado en 2020

Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma

scientific article published on 06 January 2014

Inter- and intrapatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment

scientific article published on 01 May 2019

Interim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD-L1 therapy ⬇️

artículo científico publicado en 2019

Intra-patient heterogeneity of BRAF mutation status: fact or fiction?

artículo científico publicado en 2013

Intrapatient homogeneity of BRAFV600E expression in melanoma.

artículo científico publicado en 2014

Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine.

artículo científico publicado en 2012

Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?

artículo científico publicado en 2016

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

artículo científico publicado en 2015

Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series

artículo científico

Ipilimumab-induced hypophysitis: early Australian experience

artículo científico publicado en 2014

Is chemotherapy still an option in the treatment of melanoma?

artículo científico publicado en 2015

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanoma

scientific article published on 01 December 2020

KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma

artículo científico publicado en 2019

Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread

Learning from clinical trials of neoadjuvant checkpoint blockade

artículo científico publicado en 2020

Leptomeningeal melanoma-A case series in the era of modern systemic therapy

artículo científico publicado en 2017

Long-Term Follow-Up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients With Advanced Melanoma: KEYNOTE-029 Part 1B

scientific article published on 30 June 2020

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib

artículo científico publicado en 2017

Long-term outcomes from the randomized phase II study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): Anti-PD1 brain collaboration (ABC) ⬇️

artículo científico publicado en 2019

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

artículo científico publicado en 2020

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

scientific article published on 18 September 2020

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma

article

Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors

scientific article published on 22 April 2020

Lung encasement by metastatic osteoblastic sarcoma

artículo científico publicado en 2007

MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy

artículo científico publicado en 2017

MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer

scientific article published on 01 June 2020

Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

scientific article published on 21 October 2019

Making a difference to many

artículo científico publicado en 2019

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy

scientific article published on 06 May 2020

Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia

artículo científico publicado en 2020

Meeting report from the Society for Melanoma Research 2012 Congress, Hollywood, California.

artículo científico publicado en 2013

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

artículo científico publicado en 2016

Melanoma brain metastases: the outcome of whole brain radiation therapy in the era of effective systemic therapy

artículo científico publicado en 2021

Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis

artículo científico publicado en 2020

Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual

artículo científico publicado en 2017

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

artículo científico publicado en 2012

Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma.

artículo científico publicado en 2017

Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis

artículo científico publicado en 2021

Molecular Genomic Profiling of Melanocytic Nevi

scientific article published on 14 February 2019

Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker

artículo científico publicado en 2020

Morphologic and immunohistochemical (IHC) changes in metastatic melanoma (MM) tissue and associations with clinical outcome in patients (pts) on BRAF inhibitors (BRAFi)

Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis

artículo científico publicado en 2020

Multi-Trait Genetic Analysis Identifies Autoimmune Loci Associated with Cutaneous Melanoma

artículo científico publicado en 2021

Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies

artículo científico

Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors

artículo científico publicado en 2015

Multiplex melanoma families are enriched for polygenic risk

scientific article published on 27 July 2020

Musculoskeletal immune-related adverse events with use of checkpoint inhibitors in malignancy

artículo científico publicado en 2020

Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients.

artículo científico publicado en 2017

Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

scientific article published on 03 June 2019

Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

scientific article published on 01 July 2019

New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma.

artículo científico publicado en 2014

New combinations and immunotherapies for melanoma: latest evidence and clinical utility.

artículo científico

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials

artículo científico publicado en 2017

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma

article

Nivolumab in previously untreated melanoma without BRAF mutation

artículo científico publicado en 2015

Novel Immune Targets in Melanoma-Response

artículo científico publicado en 2019

Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma

artículo científico publicado en 2012

OTHR-08. PREDICTION OF RISK OF CENTRAL NERVOUS SYSTEM METASTASIS FOR AJCC 8TH EDITION STAGE III MELANOMA PATIENTS

scholarly article

Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation - Authors' reply

scientific article published on 01 August 2018

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

artículo científico publicado en 2018

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

artículo científico publicado en 2017

Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists.

artículo científico publicado en 2016

Optimum dosing of ipilimumab in melanoma: too little, too late?

scientific article published on 27 March 2017

Oral malignant gastrointestinal neuroectodermal tumour with junctional component mimicking mucosal melanoma

artículo científico publicado en 2018

Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial

artículo científico publicado en 2018

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

artículo científico publicado en 2014

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

artículo científico publicado en 2016

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

artículo científico publicado en 2017

PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors

artículo científico publicado en 2017

PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.

artículo científico publicado en 2015

PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma

artículo científico publicado en 2016

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials

article

Paradoxical oncogenesis: are all BRAF inhibitors equal?

artículo científico publicado en 2013

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma

artículo científico publicado en 2018

Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma

Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial

scientific article published on 27 March 2019

Patterns of Response and Progression to Immunotherapy

artículo científico publicado en 2018

Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib

artículo científico publicado en 2013

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

artículo científico publicado en 2017

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

scientific article published on 22 July 2019

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy)

artículo científico publicado en 2020

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

artículo científico publicado en 2013

Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia

artículo científico publicado en 2019

Pharmacokinetic and pharmacodynamic analysis of preoperative therapy with dabrafenib alone and in combination with trametinib in patients with BRAF mutation–positive melanoma with metastases to the brain (BRV116521)

artículo científico publicado en 2014

Phase I Study of MK-4166, an Anti-Human Glucocorticoid-Induced Tumor Necrosis Factor Receptor Antibody, Alone or With Pembrolizumab in Advanced Solid Tumors

artículo científico publicado en 2020

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors

article published in 2010

Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436)

article by J. R. Infante et al published 20 June 2011 in Journal of Clinical Oncology

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

artículo científico publicado en 2012

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma

artículo científico publicado en 2013

Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results.

artículo científico publicado en 2014

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

artículo científico publicado en 2016

Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients

artículo científico publicado en 2019

Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator

scholarly article

Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors

artículo científico publicado en 2012

Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.

artículo científico publicado en 2014

Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients

artículo científico publicado en 2020

Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials

artículo científico publicado en 2019

Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma

artículo científico publicado en 2017

Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases

scientific article published on 26 November 2018

Primary medical therapy for BRAFV600E-mutant melanoma brain metastases-is this good enough? - Authors' reply

artículo científico publicado en 2017

Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit

artículo científico publicado en 2020

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

artículo científico publicado en 2011

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma

scientific article published on 11 June 2019

Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials.

artículo científico publicado en 2016

Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis

artículo científico publicado en 2018

Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

scientific article published on 01 August 2019

Radiological manifestations of immune-related adverse effects observed in patients with melanoma undergoing immunotherapy.

artículo científico publicado en 2017

Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies

Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy

artículo científico publicado en 2017

Recent Developments in Melanoma Therapy.

artículo científico publicado en 2016

Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond

artículo científico

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study

artículo científico publicado en 2018

Rechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquired resistance to IPI+PD1 immunotherapy ⬇️

artículo científico publicado en 2019

Recurrent bowel obstruction: unusual presentation of pembrolizumab-induced pancreatitis in annular pancreas.

artículo científico publicado en 2017

Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas

article

Reinvigorating tumour-infiltrating lymphocytes from checkpoint inhibitor resistant melanomas

artículo científico publicado en 2018

Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value

scientific article published on 18 April 2020

Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.

artículo científico publicado en 2017

Reply to A. Shinde et al

artículo científico publicado en 2019

Reply to E. Hindié and K.R. Hess

artículo científico publicado en 2019

Reply to M. Perier-Muzet et al

scientific article published on 02 September 2014

Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma

Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy.

artículo científico publicado en 2016

Resistance to PD1/PDL1 checkpoint inhibition.

artículo científico publicado en 2016

Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?

artículo científico publicado en 2016

Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis

artículo científico publicado en 2014

Response to Letter to the Editor for "Checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes"

scientific article published on 19 March 2020

SIRT6 haploinsufficiency induces BRAF melanoma cell resistance to MAPK inhibitors via IGF signalling

scientific article published in Nature Communications

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

artículo científico publicado en 2016

Safety and Activity of Combined Radiation Therapy (RT) and Anti-PD-1 Antibodies (PD-1) in Patients (pts) With Metastatic Melanoma

Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.

artículo científico publicado en 2017

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma

artículo científico publicado en 2011

Sentinel node biopsy for melanoma: The medical oncology perspective

Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy

artículo científico publicado en 2019

Solution conformation of the antitumor drug streptonigrin.

artículo científico publicado en 1993

Somatic Hypermutation of the YAP Oncogene in a Human Cutaneous Melanoma

artículo científico publicado en 2019

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.

artículo científico

Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials

artículo científico publicado en 2014

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial

scientific article published on 01 February 2019

Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy.

artículo científico publicado en 2017

Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019

scientific article published on 13 March 2020

Survival of patients with advanced metastatic melanoma: The impact of novel therapies

artículo científico

Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.

artículo científico publicado en 2017

Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies

artículo científico publicado en 2017

Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy?

scientific article published on 25 February 2015

Synthesis, properties and complexation studies on 3-amino-6,6′-dimethyl-2,2′-bipyridine

Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors

artículo científico publicado en 2013

Systemic therapies for melanoma brain metastases: which drug for whom and when?

artículo científico

Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice.

artículo científico publicado en 2017

Systemic treatment for BRAF-mutant melanoma: where do we go next?

artículo científico publicado en 2014

TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells

artículo científico publicado en 2014

Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signaling

artículo científico publicado en 2014

Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations

artículo científico publicado en 2019

Targeted agents and immunotherapies: optimizing outcomes in melanoma

artículo científico publicado en 2017

Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists

artículo científico publicado en 2016

Targeted therapy for the adjuvant treatment of stage III BRAF-mutated melanoma

artículo científico publicado en 2018

Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis.

artículo científico publicado en 2017

Targeting BRAF for patients with melanoma.

artículo científico publicado en 2011

Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells.

artículo científico publicado en 2016

Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma.

artículo científico

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.

artículo científico publicado en 2016

Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model

scientific article published on 02 April 2020

The "Tricky Business" of Identifying Mechanisms of Resistance to Anti-PD-1.

artículo científico publicado en 2017

The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

article

The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma

scientific article published on 29 November 2019

The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis

artículo científico publicado en 2015

The impact of multiple primary cutaneous melanomas on survival of 2,942 patients with metastatic melanoma

The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma

artículo científico publicado en 2023

The molecular profile of metastatic melanoma in Australia

artículo científico publicado en 2016

The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence

artículo científico publicado en 2020

The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.

artículo científico publicado en 2014

The role of systemic therapies in the management of melanoma brain metastases.

artículo científico

The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.

artículo científico publicado en 2017

The state of melanoma: challenges and opportunities

artículo científico publicado en 2016

The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma

artículo científico publicado en 2015

The tumour immune landscape and its implications in cutaneous melanoma

scientific article published on 16 September 2020

The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation

artículo científico publicado en 2014

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials

artículo científico publicado en 2017

Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis ⬇️

artículo científico publicado en 2019

Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition

scientific article published on 20 April 2020

Treatment of melanoma brain metastases: a new paradigm.

artículo científico

Triple jeopardy for people with albinism

scientific article published on 01 September 2016

Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma

artículo científico publicado en 2020

Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma

scientific article published on 14 November 2020

Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.

artículo científico publicado en 2015

Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).

artículo científico publicado en 2013

Tumor mutation burden and structural chromosomal aberrations are not associated with T-cell density or patient survival in acral, mucosal, and cutaneous melanomas

scientific article published on 11 September 2020

Tumor-associated B-cells induce tumor heterogeneity and therapy resistance

artículo científico publicado en 2017

Tumour gene expression signature in primary melanoma predicts long-term outcomes

artículo científico publicado en 2021

Uncovering the complex relationship between balding, testosterone and skin cancers in men

artículo científico publicado en 2023

Unraveling the prognostic heterogeneity in patients with advanced melanoma between Australia (OZ) and the United States (US): Preliminary report of the PHAMOUS study

article

Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites

artículo científico publicado en 2022

WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.

artículo científico publicado en 2014

Welcome to the New Year!

artículo científico publicado en 2016

Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours

artículo científico publicado en 2020

Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility

artículo científico publicado en 2018

Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets

scientific article published on 18 July 2019

Whole-genome landscapes of major melanoma subtypes.

artículo científico publicado en 2017

Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity

scientific article published on 16 October 2020

X-ray structure of the zinc complex of the central metal chelation site of the antitumour drug streptonigrin

bcGST-an interactive bias-correction method to identify over-represented gene-sets in boutique arrays

scientific article published on 01 April 2019

sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

artículo científico publicado en 2016

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda